Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 21, 2026, titled "Zydus launches Semaglutide Injection in an innovative, reusable multi-dose pen device in India".
Press Release Mar 21 2026
Filed with NSE · · 3 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced the launch of Semaglutide Injection in an innovative, reusable multi-dose pen device in India. The drug will be marketed under the brand names SEMAGLYNTM, MASHEMATM, and ALTERMETM, following patent expiry. This new pen device allows for convenient dosage adjustments, improving patient adherence and reducing therapy costs. The launch addresses significant health challenges in India, particularly concerning diabetes and obesity.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Mar 19 2026
- AeroDel signs exclusive licensing arrangement with Zydus for launching Aerolife Mini™, India's First Foldable, 'Always Attached' pMDI Enhancer
- Press Release Mar 18 2026
- Press Release Mar 17 2026
- Press Release Mar 16 2026
Later from Zydus Lifesciences
- Press Release Apr 08 2026
- Press Release Apr 16 2026
- Press Release Apr 25 2026
- Press Release May 06 2026
- Press Release May 19 2026
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences